AS
EGRX

Altshuler Shaham’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Altshuler Shaham’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-617
Closed -$27K – 550
2022
Q2 		$27K Sell
617
-185
-23% -$8.5K ﹤0.01% 353
2022
Q1 		$40K Sell
802
-202
-20% -$9.7K ﹤0.01% 418
2021
Q4 		$51K Buy
+1,004
New +$52K ﹤0.01% 416
2020
Q1 		– Sell
-251
Closed -$15K – 635
2019
Q4 		$15K Buy
251
+83
+49% +$4.95K ﹤0.01% 291
2019
Q3 		$9K Buy
+168
New +$9.45K ﹤0.01% 312

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Altshuler Shaham's EGRX Position: Q3 2022 in Review

Altshuler Shaham sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 617 shares — an estimated $27K sold.

Altshuler Shaham first reported a position in EGRX in Q3 2019 and held it in 5 quarters. The position peaked at $51K in Q4 2021. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • Altshuler Shaham reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Altshuler Shaham sold 617 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $27K.
  • Altshuler Shaham first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2019 and held it in 5 quarters.
  • Altshuler Shaham's Eagle Pharmaceuticals, Inc. position peaked at $51K in Q4 2021.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Altshuler Shaham's 13F filing for Q3 2022, filed 14 Nov 2022.